Genmab — Maj 2019
-
Third Quarter Update
• September: Based on encouraging signs of early activity, one of the lung cancer cohorts in the
ongoing Phase I/II study of enapotamab vedotin will be expanded. In addition, cohorts in mixed
solid tumors and ovarian cancer are being added to the study. -
God morgen

-
God morgen.

-
God morgen

-
Er Nordnet nede?
-
Sorry..Det er min lånte labtop som driller.
-
A tuff year for many Genmab-investors.
-
Spot on Sugar.

-
Vanguard ligger lige under 5% nu ? https://www.morningstar.com/stocks/XCSE/GEN/quote.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind